Brightspring Health Services, Inc. · NASDAQ:BTSG
Brightspring Health Services — Q2 2026 Earnings Presentation
14 slides from Brightspring Health Services's earnings presentation, Jul 31, 2026
Slide 1: Second Quarter 2026 Earnings Presentation
No Image No Image Second Quarter 2026 Earnings Presentation July 31, 2026 1
Slide 2: Forward-Looking Statements; Non-GAAP Financial Information
No Image Forward-Looking Statements; Non-GAAP Financial Information Forward-Looking Statements • factors outside of our control, including those listed, which have required and could in the future require us to record an asset impairment of goodwill; • No Image a pandemic, epidemic, or outbreak of a
Slide 3: A leading pharmacy and health care provider in the U.S.
No Image A leading pharmacy and health care provider in the U.S., serving large and growing markets that have significant unmet needs, with high-quality and integrated services that improve outcomes and reduce cost 3
Slide 4: BrightSpring: A Leader in Home & Community Healthcare
No Image BrightSpring: A Leader in Home & Community Healthcare Providing Needed Solutions ✓ Serving large and growing healthcare populations, characterized by high-cost, high-acuity, and significant complexity, with patient-centered and high-quality services delivered in preferred and lower-cost hom
Slide 5: BrightSpring Financial Highlights
No Image BrightSpring Financial Highlights Second Quarter 2026 $3,873M 23.0% $206M 44.2% Revenue Revenue Growth Adj. EBITDA Adj. EBITDA Growth Second Quarter 2026 ($ in millions) Y/Y Growth Pharmacy Solutions Pharmacy Solutions Revenue $3,407 +22.1% acy Hom arm e an Specialty and Infusion n Ph dC 2,
Slide 6: Q2 2026 Revenue and Adjusted EBITDA Results
No Image Q2 2026 Revenue and Adjusted EBITDA Results ($ in millions) Revenue Total Revenue +23.0% $3,873 $3,148 $466 +30.3% $358 Provider Services Pharmacy Solutions +22.1% $3,407 $2,790 Q2 2025 Q2 2026 ($ in millions) Adjusted EBITDA(1) Adj. EBITDA 4.5% 5.3% margin(1) Total Adjusted EBITDA $206 +44
Slide 7: Q2 2026 Pharmacy Solutions Segment Performance
No Image Q2 2026 Pharmacy Solutions Segment Performance ($ in millions) Q2 2026 Revenue Specialty and Infusion Pharmacy Home and Community Pharmacy Pharmacy Solutions(1) +22.1% $3,407 $2,790 (8.0%) $540 $587 Business Metrics $2,868 +30.1% $2,203 Prescriptions dispensed 10,844 (thousands) (0.1%) y/y
Slide 8: Q2 2026 Provider Services Segment Performance
No Image Q2 2026 Provider Services Segment Performance ($ in millions) Q2 2026 Revenue Home Health Care Rehab Care Personal Care Provider Services(1) +30.3% $466 $358 $107 +6.6% Business Metrics $100 $82 $73 +11.9% +50.5% $278 Home Health Care average 46,448 $185 +54.4% y/y daily census 30,085 in 2Q
Slide 9: Financial Performance: Three Months Ended June 30, 2026
No Image Financial Performance: Three Months Ended June 30, 2026 Three Months Ended June 30, 2025 vs. Three Months Ended June 30, 2026 Pharmacy Solutions Provider Services Three Months Three Months Three Months Three Months ($ in millions, Change ($ in millions, Change Ended June 30, Ended June 30,
Slide 10: 2026 Guidance, Excluding Community Living
No Image 2026 Guidance, Excluding Community Living 2026 Fiscal Year Guidance Updated FY 2026 Updated FY 2026 Prior FY 2026 Guidance1 Guidance1 Guidance1 ($ in millions) Provided February 27, 2026 Provided May 1, 2026 Provided July 31, 2026 $12,600 – $13,100 $12,850 – $13,300 $13,200 – $13,500 Pharma
Slide 11: De-leveraging Update and Capital Allocation Priorities
No Image De-leveraging Update and Capital Allocation Priorities De-leveraging driven by operational performance and capital allocation • Capex investments: 1% of revenue Long-Term Pre IPO / Post-Equity and Debt Transactions Current Cash Flow Leverage • Sustainable net working capital position Levera
Slide 12: Appendix
Appendix 12
Slide 13: Non-GAAP Reconciliations
No Image Non-GAAP Reconciliations For the Three Months Ended For the Six Months Ended ($ in thousands) June 30, 2025 June 30, 2026 June 30, 2025 June 30, 2026 Net Income from Continuing Operations $ 8,541 $ 86,604 $ 17,757 $ 160,887 Income Tax Expense 1,238 6,908 998 15,459 Interest Expense, net 38,
Slide 14: Basic and Diluted Weighted-Average Shares Outstanding Calculation
No Image Basic and Diluted Weighted-Average Shares Outstanding Calculation utilized in calculating Diluted EPS to Adjusted EPS For the Three Months Ended (in thousands) Jun 30, 2025 Sept 30, 2025 Dec 31, 2025 Mar 31, 2026 Jun 30, 2026 Publicly owned shares (excluding KKR) 98,627 103,138 130,026 151,
BrightSpring Health Services — Q2 2026 Earnings Presentation on 6ix